CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

After Intellia Therapeutics paused a pair of phase 3 trials for its CRISPR therapy in response to a liver safety signal, the ...

Explore how oligonucleotides are reshaping therapeutics, diagnostics and CRISPR with rapid, scalable and personalized ...

Two days after Intellia voluntarily paused dosing due to safety concerns, the regulator stepped in with an official hold that ...

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $62.56, moving -2.51% from the previous trading session. Elsewhere, the Dow saw a downswing of 0.16%, while the tech-heavy Nasdaq ...

CRISPR-Cas systems, defense systems in bacteria, have become a plentiful source of technologies for molecular diagnostics. Researchers have now expanded this extensive toolbox further. Their novel ...

A study volunteer receiving Intellia’s transthyretin amyloidosis treatment was hospitalized due to severe signs of liver ...

The goal of gene therapy is to permanently cure hereditary diseases. One of the most promising technologies for this is the ...

Like the find-and-replace feature of a word processor, CRISPR-based engineering allows scientists to quickly and efficiently edit DNA sequences with base pair precision. Lauded as the great ...

Brendan Jones Ph.D., Xianfeng Morgan Xu, Ph.D. The past week was a truly remarkable week for the CRISPR gene editing field. New developments have reshaped both the legal and scientific landscapes for ...

Both CRSP and NTLA are advancing in vivo gene editing therapies targeting large markets, with financial stability supporting ...

A research team has successfully engineered a japonica rice variety using CRISPR/Cas9 to simultaneously optimize plant ...